Alar
昱展新藥生技股份有限公司
Alar is a Taiwan TPEx-listed biotechnology company; its most advanced asset is ALA-3000 (Phase 2 trial application submitted, Treatment-resistant depression), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ALA-3000 | — | Phase 2 trial application submitted | Treatment-resistant depression | United States | 2026-10-16 | Company disclosure |
| ALA-1000 | — | — | — | — | 2026-03-04 | Company disclosure |
Key events
- Business update (company filing)
- Business update (company filing)
- Business update (company filing)
Related Drugnews articles
No related articles in this language.